AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update
Digestive and Liver Disease · 2026-05 · 58 (5) · 599-607
DOI: 10.1016/j.dld.2026.02.014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestive and Liver Disease, 2026-05. Verfasst von Associazione Italiana per lo Studio del Fegato (AISF). Hauptthemen laut MEDLINE: Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Associazione Italiana per lo Studio del Fegato (AISF) (2026). AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update. Digestive and Liver Disease, 58(5), 599-607. https://doi.org/10.1016/j.dld.2026.02.014
Vancouver
Associazione Italiana per lo Studio del Fegato (AISF). AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update. Digestive and Liver Disease. 2026;58(5):599-607. doi:10.1016/j.dld.2026.02.014
BibTeX
@article{AssociazioneItalianaperloStudiodelFegatoAISF2026,
author = {Associazione Italiana per lo Studio del Fegato (AISF), Associazione Italiana per lo Studio del Fegato (AISF)},
title = {AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update},
journal = {Digestive and Liver Disease},
year = {2026},
volume = {58},
number = {5},
pages = {599--607},
doi = {10.1016/j.dld.2026.02.014}
}
EUVIMED